{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T14:51:52Z","timestamp":1785595912231,"version":"3.56.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-78741-4","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T16:04:10Z","timestamp":1730909050000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of renal impairment on early development of severe neutropenia with trifluridine\/tipiracil treatment for metastatic colorectal cancer"],"prefix":"10.1038","volume":"14","author":[{"given":"Yoshitaka","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoh","family":"Takekuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"key":"78741_CR1","doi-asserted-by":"publisher","unstructured":"Mayer, R. J. et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N. Engl. J. Med. 372(20), 1909\u20131919 (2015). https:\/\/doi.org\/10.1056\/NEJMoa1414325, Pubmed: 25970050.","DOI":"10.1056\/NEJMoa1414325"},{"issue":"10","key":"78741_CR2","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/S1470-2045(12)70345-5","volume":"13","author":"T Yoshino","year":"2012","unstructured":"Yoshino, T. et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 13 (10), 993\u20131001. https:\/\/doi.org\/10.1016\/S1470-2045(12)70345-5 (2012). Pubmed: 22951287.","journal-title":"Lancet Oncol."},{"key":"78741_CR3","doi-asserted-by":"publisher","unstructured":"Prager, G. W. et al. Trifluridine-Tipiracil and Bevacizumab in refractory metastatic colorectal cancer. N. Engl. J. Med. 388(18), 1657\u20131667 (2023). https:\/\/doi.org\/10.1056\/NEJMoa2214963, Pubmed: 37133585.","DOI":"10.1056\/NEJMoa2214963"},{"issue":"3","key":"78741_CR4","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S1470-2045(19)30827-7","volume":"21","author":"P Pfeiffer","year":"2020","unstructured":"Pfeiffer, P. et al. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol.  21 (3), 412\u2013420 (2020). 2045(19)30827-7, Pubmed: 31999946.","journal-title":"Lancet Oncol."},{"issue":"6","key":"78741_CR5","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.3892\/or.2014.3487","volume":"32","author":"N Tanaka","year":"2014","unstructured":"Tanaka, N. et al. Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncol. Rep. 32 (6), 2319\u20132326. https:\/\/doi.org\/10.3892\/or.2014.3487 (2014). Pubmed: 25230742.","journal-title":"Oncol. Rep."},{"issue":"10","key":"78741_CR6","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/s0006-2952(00)00253-7","volume":"59","author":"M Fukushima","year":"2000","unstructured":"Fukushima, M. et al. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2\u2019-deoxyribonucleosides. Biochem. Pharmacol. 59 (10), 1227\u20131236. https:\/\/doi.org\/10.1016\/s0006-2952(00)00253-7 (2000). Pubmed: 10736423.","journal-title":"Biochem. Pharmacol."},{"key":"78741_CR7","doi-asserted-by":"publisher","unstructured":"Lee, J. J. et al. Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry. Cancer Chemother. Pharmacol. 77(3), 515\u2013526 (2016). https:\/\/doi.org\/10.1007\/s00280-016-2965-2, Pubmed: 26787503.","DOI":"10.1007\/s00280-016-2965-2"},{"key":"78741_CR8","doi-asserted-by":"publisher","unstructured":"Yoshino, T. et al. Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine\/tipiracil in the RECOURSE and J003 trials. Ann. Oncol. 31(1), 88\u201395 (2020). https:\/\/doi.org\/10.1016\/j.annonc.2019.10.005, Pubmed: 31912801.","DOI":"10.1016\/j.annonc.2019.10.005"},{"key":"78741_CR9","doi-asserted-by":"publisher","unstructured":"Makihara, K., Fukui, R., Uchiyama, H., Shigeoka, Y. & Toyokawa, A. Decreased percentage of neutrophil is a predict factor for the efficacy of trifluridine and tipiracil hydrochloride for pretreated metastatic colorectal cancer. J. Gastrointest. Oncol. 10(5), 878\u2013885 (2019). https:\/\/doi.org\/10.21037\/jgo.2019.04.04, Pubmed: 31602325.","DOI":"10.21037\/jgo.2019.04.04"},{"key":"78741_CR10","doi-asserted-by":"publisher","unstructured":"Hamauchi, S. et al. Neutropenia as a predictive factor in metastatic colorectal Cancer treated with TAS-102. Clin. Colorectal Cancer 16(1), 51\u201357 (2017). https:\/\/doi.org\/10.1016\/j.clcc.2016.07.005, Pubmed: 27522626.","DOI":"10.1016\/j.clcc.2016.07.005"},{"issue":"5","key":"78741_CR11","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3892\/ol.2021.13044","volume":"22","author":"D Kamiimabeppu","year":"2021","unstructured":"Kamiimabeppu, D. et al. Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine\/tipiracil plus bevacizumab. Oncol. Lett. 22 (5), 783. https:\/\/doi.org\/10.3892\/ol.2021.13044 (2021). Pubmed: 34594424.","journal-title":"Oncol. Lett."},{"key":"78741_CR12","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00280-021-04308-z","volume":"88(3)","author":"MW Saif","year":"2021","unstructured":"Saif, M. W. et al. A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine\/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment. Cancer Chemother. Pharmacol.  88,3  485\u2013497. https:\/\/doi.org\/10.1007\/s00280-021-04308-z (2021). Pubmed: 34097100.","journal-title":"Cancer Chemother. Pharmacol."},{"key":"78741_CR13","doi-asserted-by":"publisher","unstructured":"Yoshino, T. et al. Post-marketing surveillance study of trifluridine\/tipiracil in patients with metastatic colorectal cancer. Jpn. J. Clin. Oncol. 51(5), 700\u2013706 (2021). https:\/\/doi.org\/10.1093\/jjco\/hyaa243, Pubmed: 33438718.","DOI":"10.1093\/jjco\/hyaa243"},{"key":"78741_CR14","doi-asserted-by":"publisher","unstructured":"Yasue, F. et al. Risk factors contributing to the development of neutropenia in patients receiving oral trifluridine-tipiracil (TAS-102) chemotherapy for advanced\/recurrent colorectal cancer. Pharmazie 73(3), 178\u2013181 (2018).  https:\/\/doi.org\/10.1691\/ph.2018.7908, Pubmed: 29544568.","DOI":"10.1691\/ph.2018.7908"},{"key":"78741_CR15","doi-asserted-by":"publisher","unstructured":"O\u2019Malley, M., Healy, P., Daignault, S. & Ramnath, N. Cigarette smoking and gemcitabine-induced neutropenia in advanced solid tumors. Oncology 85(4), 216\u2013222 (2013). https:\/\/doi.org\/10.1159\/000355107, Pubmed: 24080957.","DOI":"10.1159\/000355107"},{"key":"78741_CR16","doi-asserted-by":"crossref","unstructured":"de Graan, A. J. et al. Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy. Clin. Cancer Res. 18(16), 4425\u20134432 10.1158\/1078\u2009\u2013\u20090432.CCR-12-0728, Pubmed: 22645049. (2012).","DOI":"10.1158\/1078-0432.CCR-12-0728"},{"key":"78741_CR17","doi-asserted-by":"publisher","unstructured":"van der Bol, J. M. et al. Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J. Clin. Oncol.  25(19), 2719\u20132726 (2007). https:\/\/doi.org\/10.1200\/JCO.2006.09.6115, Pubmed: 17563393.","DOI":"10.1200\/JCO.2006.09.6115"},{"key":"78741_CR18","doi-asserted-by":"publisher","unstructured":"Saito, Y., Takekuma, Y., Kobayashi, M., Komatsu, Y. & Sugawara, M. Detection of risk factors related to administration suspension and severe neutropenia in gemcitabine and nab-paclitaxel treatment. Support. Care Cancer 29(6), 3277\u20133285 (2021). https:\/\/doi.org\/10.1007\/s00520-020-05842-x, Pubmed: 33104920.","DOI":"10.1007\/s00520-020-05842-x"},{"key":"78741_CR19","doi-asserted-by":"publisher","unstructured":"Nose, Y. et al. Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD\/TPI plus bevacizumab: a retrospective study. Cancer Chemother. Pharmacol. 86(3), 427\u2013433 (2020). https:\/\/doi.org\/10.1007\/s00280-020-04129-6, Pubmed: 32816155.","DOI":"10.1007\/s00280-020-04129-6"},{"key":"78741_CR20","doi-asserted-by":"publisher","unstructured":"Saito, Y., Takekuma, Y., Shinagawa, N. & Sugawara, M. Evaluation of risk factors associated with carboplatin and nab-paclitaxel treatment suspension in patients with non-small cell lung cancer. Support. Care Cancer  30(5), 4081\u20134088 (2022). https:\/\/doi.org\/10.1007\/s00520-021-06757-x, Pubmed: 35066667.","DOI":"10.1007\/s00520-021-06757-x"},{"key":"78741_CR21","doi-asserted-by":"publisher","unstructured":"Chen, L. J. et al. Association of olypharmacy with colorectal cancer survival among older patients. Oncologist  26(12), e2170-e2180 (2021). https:\/\/doi.org\/10.1002\/onco.13961, Pubmed: 34476870.","DOI":"10.1002\/onco.13961"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78741-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78741-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78741-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T16:06:40Z","timestamp":1730909200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78741-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["78741"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-78741-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,6]]},"assertion":[{"value":"22 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YS, YT, and MS have no conflicts of interest. YK reports. grants and personal fees from Ono, Taiho, Chugai, Eli Lilly, Daiichi Sankyo, Nippon Kayaku, and MSD; personal fees from Bayer and Yakult; and grants from IQVIA, Astellas, Nippon Zoki, Shionogi, EPS, Eisai, and the National Cancer Center outside of the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures involving human participants performed in this study were carried out in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study, formal consent was waived by the Ethical Review Board for Life Science and Medical Research of the Hokkaido University Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study Formal consent was not required for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"26990"}}